Abstract
Type 2 diabetes mellitus (T2DM) is mainly associated with impaired insulin secretion by the pancreatic β-cells, insulin resistance and elevated hepatic gluconeogenesis. Incretin based treatments for T2DM are now widely investigated and used. The incretin based therapies mainly include incretin hormones which are glucose-dependent insulinotropic peptides (GIP) and glucagon like peptide-1 (GLP-1) released from the endocrinal cells in the small intestine in response to food intake. The main function of GLP-1 is to induce insulin secretion and suppress glucagon secretion. This review describes the different formulation approaches for oral delivery of incretins and the limitations associated with this route of administration. We highlight the use of micro and nanosystems to efficiently deliver the incretins orally. Furthermore, we present several examples of the significant potential of these systems in pharmaceutical applications.
Keywords: Glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 (GLP-1), incretins, lipids, microparticles, mesoporous materials, nanoparticles, oral drug delivery, polymers.
Current Pharmaceutical Biotechnology
Title:Antihyperglycemic Potential of Incretins Orally Delivered via Nano and Microsystems and Subsequent Glucoregulatory Effects
Volume: 15 Issue: 7
Author(s): Francisca Araujo, Neha Shrestha, Pedro L. Granja, Jouni Hirvonen, Hélder A. Santos and Bruno Sarmento
Affiliation:
Keywords: Glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 (GLP-1), incretins, lipids, microparticles, mesoporous materials, nanoparticles, oral drug delivery, polymers.
Abstract: Type 2 diabetes mellitus (T2DM) is mainly associated with impaired insulin secretion by the pancreatic β-cells, insulin resistance and elevated hepatic gluconeogenesis. Incretin based treatments for T2DM are now widely investigated and used. The incretin based therapies mainly include incretin hormones which are glucose-dependent insulinotropic peptides (GIP) and glucagon like peptide-1 (GLP-1) released from the endocrinal cells in the small intestine in response to food intake. The main function of GLP-1 is to induce insulin secretion and suppress glucagon secretion. This review describes the different formulation approaches for oral delivery of incretins and the limitations associated with this route of administration. We highlight the use of micro and nanosystems to efficiently deliver the incretins orally. Furthermore, we present several examples of the significant potential of these systems in pharmaceutical applications.
Export Options
About this article
Cite this article as:
Araujo Francisca, Shrestha Neha, Granja L. Pedro, Hirvonen Jouni, Santos A. Hélder and Sarmento Bruno, Antihyperglycemic Potential of Incretins Orally Delivered via Nano and Microsystems and Subsequent Glucoregulatory Effects, Current Pharmaceutical Biotechnology 2014; 15 (7) . https://dx.doi.org/10.2174/1389201015666140915150312
DOI https://dx.doi.org/10.2174/1389201015666140915150312 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Antiplatelet Agents in the Management of Patients Receiving Intracardiac Closure Devices
Current Pharmaceutical Design Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Current Psychopharmacology Hitting the Jackpot Twice: Identifying and Patenting Gene Tests Related to Muscle Lipid Accumulation for Meat Quality in Animals and Type 2 Diabetes/Obesity in Humans
Recent Patents on DNA & Gene Sequences Hormones and the Autonomic Nervous System are Involved in Suprachiasmatic Nucleus Modulation of Glucose Homeostasis
Current Diabetes Reviews Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Current Pharmaceutical Design Diabetic Retinopathy and Angiogenesis
Current Diabetes Reviews A Systematic Review of Analytical Profiles of SGLT2 Inhibitors and their Combinations for Treatment of Type 2 Diabetes Mellitus
Current Pharmaceutical Analysis MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations
Current Pharmaceutical Biotechnology T-type Ca Channel Blockers in Patients with Chronic Kidney Disease in Clinical Practice
Current Hypertension Reviews Biological Mechanisms Linking Alzheimer's Disease and Type-2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Circulating Levels of Uric Acid and Risk for Metabolic Syndrome
Current Diabetes Reviews Implantable Continuous Glucose Sensors
Current Diabetes Reviews Evaluation of Mucin as a Release Enhancer for Rectal Delivery of Glibenclamide
Current Drug Delivery Population Approaches for Detecting Glucose Disorders
Current Diabetes Reviews Bone Metabolism and Histomorphometric Changes in Murine Models Treated with Sclerostin Antibody: A Systematic Review
Current Drug Targets Intein-Mediated Expression and Purification of an Analog of Glucagon-like Peptide-1 in Escherichia coli
Protein & Peptide Letters Production of Pancreatic Beta-Cells from Stem Cells
Current Diabetes Reviews Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis
Current Pharmaceutical Biotechnology Development of Insulin Resistance During Aging: Involvement of Central Processes and Role of Adipokines
Current Protein & Peptide Science